Literature DB >> 30227749

Gut microbiota modulates drug pharmacokinetics.

Juanhong Zhang1,2, Junmin Zhang1, Rong Wang1,2.   

Abstract

Gut microbiota, one of the determinants of pharmacokinetics, has long been underestimated. It is now generally accepted that the gut microbiota plays an important role in drug metabolism during enterohepatic circulation either before drug absorption or through various microbial enzymatic reactions in the gut. In addition, some drugs are metabolized by the intestinal microbiota to specific metabolites that cannot be formed in the liver. More importantly, metabolizing drugs through the gut microbiota prior to absorption can alter the systemic bioavailability of certain drugs. Therefore, understanding intestinal flora-mediated drug metabolism is critical to interpreting changes in drug pharmacokinetics. Here, we summarize the effects of gut microbiota on drug pharmacokinetics, and propose that the influence of intestinal flora on pharmacokinetics should be organically related to the therapeutic effects and side effects of drugs. More importantly, we could rationally perform the strategy of intestinal microflora-mediated metabolism to design drugs.

Keywords:  Gut microbiota; drug metabolism; drug pharmacokinetics; therapeutic effect; toxicity

Mesh:

Year:  2018        PMID: 30227749     DOI: 10.1080/03602532.2018.1497647

Source DB:  PubMed          Journal:  Drug Metab Rev        ISSN: 0360-2532            Impact factor:   4.518


  24 in total

Review 1.  Predicting and Understanding the Human Microbiome's Impact on Pharmacology.

Authors:  Reese Hitchings; Libusha Kelly
Journal:  Trends Pharmacol Sci       Date:  2019-06-03       Impact factor: 14.819

Review 2.  Drug-Induced Small Bowel Injury: a Challenging and Often Forgotten Clinical Condition.

Authors:  Carmelo Scarpignato; Ingvar Bjarnason
Journal:  Curr Gastroenterol Rep       Date:  2019-11-13

3.  Cecal Metabolomic Fingerprint of Unscathed Rats: Does It Reflect the Good Response to a Provocative Decompression?

Authors:  Anne-Virginie Desruelle; Sébastien de Maistre; Sandrine Gaillard; Simone Richard; Catherine Tardivel; Jean-Charles Martin; Jean-Eric Blatteau; Alain Boussuges; Sarah Rives; Jean-Jacques Risso; Nicolas Vallee
Journal:  Front Physiol       Date:  2022-05-17       Impact factor: 4.755

Review 4.  Challenges of repurposing tetracyclines for the treatment of Alzheimer's and Parkinson's disease.

Authors:  Iva Markulin; Marija Matasin; Viktorija Erdeljic Turk; Melita Salković-Petrisic
Journal:  J Neural Transm (Vienna)       Date:  2022-01-04       Impact factor: 3.850

5.  Case Report of Increased Exposure to Antiretrovirals following Sleeve Gastrectomy.

Authors:  Sarah Israel; Hila Elinav; Ram Elazary; Daniel Porat; Roni Gibori; Arik Dahan; Carmil Azran; Ehud Horwitz
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

6.  Effects of Gut Microbiome on Carcinogenic DNA Damage.

Authors:  Yun-Chung Hsiao; Chih-Wei Liu; Liang Chi; Yifei Yang; Kun Lu
Journal:  Chem Res Toxicol       Date:  2020-07-31       Impact factor: 3.739

Review 7.  Mechanism of idiosyncratic drug induced liver injury (DILI): unresolved basic issues.

Authors:  Rolf Teschke; Jack Uetrecht
Journal:  Ann Transl Med       Date:  2021-04

Review 8.  Implications of Bariatric Surgery on the Pharmacokinetics of Antiretrovirals in People Living with HIV.

Authors:  Leena Zino; Jurjen S Kingma; Catia Marzolini; Olivier Richel; David M Burger; Angela Colbers
Journal:  Clin Pharmacokinet       Date:  2022-04-11       Impact factor: 5.577

9.  Medication Management after Bariatric Surgery: Providing Optimal Patient Care.

Authors:  Daniel Porat; Arik Dahan
Journal:  J Clin Med       Date:  2020-05-17       Impact factor: 4.241

Review 10.  Potential Applications of Chitosan-Based Nanomaterials to Surpass the Gastrointestinal Physiological Obstacles and Enhance the Intestinal Drug Absorption.

Authors:  Nutthapoom Pathomthongtaweechai; Chatchai Muanprasat
Journal:  Pharmaceutics       Date:  2021-06-15       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.